TABLE 2.

Treatment of mice with anti-CXCL10 antibody suppresses tissue levels of CXCL10 during HSV-1 infection^a

Day p.i.	Tissue	Chemokine	CXCL10 levels (pg/tissue ± SEM) for treatment with:
			Anti-CXCL10 Ab	Control Ab
1	Eye	CXCL10	0.0 ± 0.0*	72 ± 26
3	Eye	CXCL10	28 ± 19*	110 ± 32
6	Eye	CXCL10	532 ± 224	934 ± 321
1	Eye	MIG	0.0 ± 0.0	0.0 ± 0.0
3	Eye	MIG	34 ± 14	82 ± 23
6	Eye	MIG	1331 ± 323	1,128 ± 342
1	Eye	VEGF	7.4 ± 3.3	8.0 ± 1.6
3	Eye	VEGF	5.7 ± 1.2*	10.1 ± 1.6
6	Eye	VEGF	4.2 ± 2.0	5.6 ± 2.2
1	TG	CXCL10	0.0 ± 0.0	0.0 ± 0.0
3	TG	CXCL10	111 ± 55	287 ± 158
6	TG	CXCL10	807 ± 225*	1,466 ± 131
1	TG	MIG	0.0 ± 0.0	0.0 ± 0.0
3	TG	MIG	128 ± 67	77 ± 29
6	TG	MIG	681 ± 164*	1,520 ± 180

^aFemale ICR mice (n = 6/group) were infected with HSV-1 (300 PFU/eye) and inoculated with 100 μg of anti-CXCL10 IgG₁ or control IgG at time 0 and 2 and 5 days p.i. At day 1, 3, or 6 p.i., the mice were euthanized and the eyes and TG were removed and assayed for chemokine content by ELISA. Numbers are in pg/tissue ± standard error of the mean. *, P < 0.05 for comparison of the anti-CXCL10- to control antibody-treated groups. This table is a summary of two experiments with n = 3 mice/group/experiment. It should be noted that neither VEGF nor MIG was detected in the eye or TG of uninfected mice. In contrast, CXCL10 was detected in the eye of uninfected mice at 20 ± 3 pg/eye but not in the TG.